These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 22366522)

  • 1. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
    Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
    J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
    Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
    van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
    Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.
    Hesse C; Ginter W; Förg T; Mayer CT; Baru AM; Arnold-Schrauf C; Unger WW; Kalay H; van Kooyk Y; Berod L; Sparwasser T
    Eur J Immunol; 2013 Oct; 43(10):2543-53. PubMed ID: 23784881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DC-SIGN mediated antigen-targeting using glycan-modified liposomes: formulation considerations.
    Joshi MD; Unger WW; van Beelen AJ; Bruijns SC; Litjens M; van Bloois L; Kalay H; van Kooyk Y; Storm G
    Int J Pharm; 2011 Sep; 416(2):426-32. PubMed ID: 21371544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ Delivery of Antigen to DC-SIGN(+)CD14(+) Dermal Dendritic Cells Results in Enhanced CD8(+) T-Cell Responses.
    Fehres CM; van Beelen AJ; Bruijns SCM; Ambrosini M; Kalay H; Bloois LV; Unger WWJ; Garcia-Vallejo JJ; Storm G; de Gruijl TD; Kooyk YV
    J Invest Dermatol; 2015 Sep; 135(9):2228-2236. PubMed ID: 25885805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting dendritic cells with antigen via dendritic cell-associated promoters.
    Moulin V; Morgan ME; Eleveld-Trancikova D; Haanen JB; Wielders E; Looman MW; Janssen RA; Figdor CG; Jansen BJ; Adema GJ
    Cancer Gene Ther; 2012 May; 19(5):303-11. PubMed ID: 22361816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.
    Cruz LJ; Tacken PJ; Pots JM; Torensma R; Buschow SI; Figdor CG
    Biomaterials; 2012 Jun; 33(16):4229-39. PubMed ID: 22410170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells.
    García-Vallejo JJ; Ambrosini M; Overbeek A; van Riel WE; Bloem K; Unger WW; Chiodo F; Bolscher JG; Nazmi K; Kalay H; van Kooyk Y
    Mol Immunol; 2013 Apr; 53(4):387-97. PubMed ID: 23103377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.
    Kretz-Rommel A; Qin F; Dakappagari N; Torensma R; Faas S; Wu D; Bowdish KS
    J Immunother; 2007 Oct; 30(7):715-26. PubMed ID: 17893564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lewis X oligosaccharides targeting to DC-SIGN enhanced antigen-specific immune response.
    Wang J; Zhang Y; Wei J; Zhang X; Zhang B; Zhu Z; Zou W; Wang Y; Mou Z; Ni B; Wu Y
    Immunology; 2007 Jun; 121(2):174-82. PubMed ID: 17371544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.
    Pérez-Díez A; Butterfield LH; Li L; Chakraborty NG; Economou JS; Mukherji B
    Cancer Res; 1998 Dec; 58(23):5305-9. PubMed ID: 9850054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses.
    Boks MA; Ambrosini M; Bruijns SC; Kalay H; van Bloois L; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Oct; 216():37-46. PubMed ID: 26151293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity.
    Schetters STT; Kruijssen LJW; Crommentuijn MHW; Kalay H; Ochando J; den Haan JMM; Garcia-Vallejo JJ; van Kooyk Y
    Front Immunol; 2018; 9():990. PubMed ID: 29867967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells.
    Aarnoudse CA; Bax M; Sánchez-Hernández M; García-Vallejo JJ; van Kooyk Y
    Int J Cancer; 2008 Feb; 122(4):839-46. PubMed ID: 17957800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4 T cell help is required for primary CD8 T cell responses to vesicular antigen delivered to dendritic cells in vivo.
    Serre K; Giraudo L; Siret C; Leserman L; Machy P
    Eur J Immunol; 2006 Jun; 36(6):1386-97. PubMed ID: 16673447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes.
    Berlyn KA; Schultes B; Leveugle B; Noujaim AA; Alexander RB; Mann DL
    Clin Immunol; 2001 Dec; 101(3):276-83. PubMed ID: 11726219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mimetic ligand selected by mRNA display targets DC-SIGN for dendritic cell-directed antigen delivery.
    Xiao L; Hung KC; Takahashi TT; Joo KI; Lim M; Roberts RW; Wang P
    ACS Chem Biol; 2013 May; 8(5):967-77. PubMed ID: 23427768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-type lectins on dendritic cells: key modulators for the induction of immune responses.
    van Kooyk Y
    Biochem Soc Trans; 2008 Dec; 36(Pt 6):1478-81. PubMed ID: 19021579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.